Biogen expects $2 million charge in third quarter 2025

Biogen Inc. (NASDAQ: BIIB) announced it expects approximately $2 million in acquired in-process research and development, upfront and milestone expenses on a pre-tax basis for the third quarter of 2025.

The biotechnology company said the estimated charge will impact both GAAP and non-GAAP net income per diluted share by approximately $0.01 per share for the quarter.

Beginning in the first quarter of 2025, Biogen started presenting acquired in-process research and development, upfront and milestone expenses as a separate line item in its financial statements. These expenses include costs from collaboration and license agreements, upfront and milestone payments, and premiums on equity securities and asset acquisitions related to in-process research and development.

The company stated it does not forecast such expenses due to uncertainty regarding the timing, occurrence and magnitude of these transactions in any given period.

Biogen noted that results for the quarter ended September 30, 2025, have not been finalized and remain subject to financial statement closing procedures. The company cautioned that final results may differ from the preliminary unaudited estimates provided.

You May Also Be Interested In

• Veraxa Biotech names Christoph Erkel as chief scientific officer
• QuantumCore signs MOU with University of Waterloo for cryogenic chips
• Tractor Supply (TSCO) Misses Q2 EPS by 4c; offers guidance